Latest News- Open-Angle Glaucoma Therapeutics Market: PGAs is expected to lead the Product segment during 2024-2028

The Open-Angle Glaucoma Therapeutics Market is being driven by Promising pipeline and recent approvals for glaucoma therapies

The Open-Angle Glaucoma Therapeutics Market is expected to grow at a CAGR of 6.1% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2362.5 million. The open-angle glaucoma therapeutics market predominantly caters to small molecule treatments, specifically prostaglandin analogs (PGAs) and non-PGAs. These drugs currently dominate the treatment landscape. However, their usage is fraught with challenges such as side effects, patient non-adherence, and high costs, thereby creating significant unmet medical needs. In response, the biologics sector is witnessing an influx of innovation, with several candidates under development. One such promising contender is Isarna Therapeutics GmbH's ISTH0036, an antisense oligonucleotide targeting TGF-beta 2. TGF-beta 2 is a key contributor to open-angle glaucoma pathogenesis. Biologics, with their potential for improved safety and efficacy, are poised to disrupt the market dynamics and address the unmet needs of open-angle glaucoma patients. 

Get more information on Open-Angle Glaucoma Therapeutics Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Product
  • PGAs
  • Non-PGAs
• Channel
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Promising pipeline and recent approvals for glaucoma therapies
• Increasing demand for combination drugs for glaucoma treatment
• Rising geriatric population

However, the market also witnesses some limitations, which are as follows:

• Advances in glaucoma surgeries
• Low patient adherence to topical medications for glaucoma
• Asymptomatic nature of open-angle glaucoma

Benefits of Buying Global Open-Angle Glaucoma Therapeutics Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Open-Angle Glaucoma Therapeutics Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Open-Angle Glaucoma Therapeutics Market focuses on treatments for Glaucoma, a leading cause of blindness, particularly among the elderly population. This market encompasses various drug classes, including Prostaglandins, Beta blockers, Alpha agonists, Combination medication, Carbonic anhydrase inhibitors, and Cholinergics, administered as topical eye drops, oral medications, or laser therapy. These treatments target the Optic nerve, reducing Intraocular pressure (IOP) to prevent Vision loss. Eye diseases such as Glaucoma can lead to blindness by damaging the Optic nerve, and treatments aim to preserve Vision through medication or surgical interventions like laser therapy or surgery.

Market Research Overview

The Open-Angle Glaucoma Therapeutics Market is a significant segment of the global pharmaceuticals industry, focusing on the development and production of drugs used to treat this sight-threatening ocular disorder. According to Technavio's market analysis, the global pharmaceuticals market size is determined by the consolidated revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing elderly population, with predictions that by 2050, approximately one-quarter of the US population and Europe's population will be over 60 years old. This demographic shift will lead to a higher prevalence of age-related ocular disorders, such as open-angle glaucoma, which damages the optic nerve and can result in vision loss.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/